Expand all sections

Ipilimumab

Yervoy

Extended indication Extension of indication to include in combination with nivolumab the treatment of adolescents (12 ye
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Ipilimumab
Domain Oncology
Reason of inclusion Indication extension
Main indication Skin cancer
Extended indication Extension of indication to include in combination with nivolumab the treatment of adolescents (12 years of age and older) for advanced (unresectable or metastatic) melanoma.
Proprietary name Yervoy
Manufacturer BMS
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date September 2022
Expected Registration July 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.